Autolus Therapeutics plc

What they do

Autolus engineers precisely targeted T cell therapies using proprietary modular T cell programming technologies for cancer and autoimmune diseases. Its lead product, AUCATZYL (obecabtagene autoleucel, or obe-cel), is a CD19 CAR T therapy approved in the US in November 2024, in the UK under conditional authorization in April 2025, and in the EU in July 2025 for adult r/r B-ALL. AUCATZYL is manufactured at the company's commercial site, the Nucleus, in Stevenage, U.K., with Cardinal Health 105, LLC as US commercial distribution partner. The company maintains books in pounds sterling and reports in US dollars under US GAAP.

Revenue drivers

• AUCATZYL US sales — Net product revenue from the US launch of AUCATZYL in adult r/r B-ALL, which began with first sale in January 2025 and is the dominant revenue source.
• AUCATZYL UK sales — Launched in the United Kingdom in January 2026 and available through routine NHS commissioning in England and Wales after NICE recommended it in November 2025.
• EU sales — Marketing authorization was granted in July 2025, but launch is on hold and no EU sales are anticipated in 2026.
• Licensing and collaboration revenue — Historical revenue included licensing and collaboration arrangements; the 10-K lists this as a prior funding source, with current revenue dominated by AUCATZYL product sales.

Recent performance

Second quarter 2026 net product revenue was $45.7 million, up 119% from $20.9 million in the same period of 2025 and up from $26.2 million in the first quarter of 2026. First-half 2026 revenue also included the first contribution from UK sales in the second quarter of that launch. The company reported a Q2 2026 net loss of $39.1 million and an accumulated deficit of $1,497.5 million as of June 30, 2026. Full-year 2025 revenue was $75.4 million against a net loss of $287.5 million, and operating cash outflow was $283.6 million.

Strategy

Management is focused on the US AUCATZYL launch in adult r/r B-ALL, expanding use within existing authorized treatment centers and adding new centers. It is also pursuing label expansion of obe-cel into pediatric B-ALL, B-NHL, lupus nephritis, systemic lupus erythematosus and progressive multiple sclerosis, plus AUTO8 in light-chain amyloidosis. In April 2026 the company announced operational efficiency initiatives, and in August 2026 it entered a five-year, interest-only senior credit facility with Perceptive Advisors for up to $250 million, with $75 million funded, to strengthen capital. FY 2026 net product revenue guidance was raised to $140–$150 million, and management targets peak adult ALL gross margins of 65–70%.

Risks

• Commercial concentration — The company depends on a single approved product, AUCATZYL, for substantially all revenue, so any failure of its US commercialization would leave little revenue base.
• Continued losses — Autolus has incurred significant net losses since inception, including $287.5 million in 2025, and expects to continue incurring losses for the foreseeable future.
• Capital needs — Management states existing cash, cash equivalents, marketable securities and the $75 million Perceptive funding are sufficient for at least the next twelve months, and warns additional financing may be needed on unfavorable terms otherwise.
• EU launch on hold — Despite EU marketing authorization in July 2025, Autolus has paused EU launch and does not anticipate EU sales of AUCATZYL in 2026, limiting near-term geographic expansion.

Outlook

Management raised FY 2026 net product revenue guidance to $140–$150 million and expects gross margin to improve toward a peak estimate of 65–70% for adult ALL. Obe-cel clinical readouts are expected, including Phase 1 CARLYSLE lupus data at ACR in Q4 2026, AUTO8 ALARIC initial data at the end of 2026, and BOBCAT MS preliminary results at ACTRIMS in Q1 2027 with a larger data set in the second half of 2027. LUMINA lupus nephritis data are expected in 2028, and Phase 2 CATULUS pediatric B-ALL data at the end of 2027.